Vistagen therapeutics stock.
Nov 30, 2023 · 2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.
About VTGN. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.Vistagen Therapeutics Inc (VTGN) stock has risen 14.79% while the S&P 500 is down -0.56% as of 12:54 PM on Monday, Dec 4. VTGN is up $0.54 from the previous closing price of $3.65 on volume of 899,778 shares. Over the past year the S&P 500 has gained 14.26% while VTGN is up 12.03%. VTGN lost -$4.76 per share the over the last …Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the last participant has completed the study protocol in its U.S. Phase 1 clinical trial of itruvone (PH10), the …Benzinga - by Vandana Singh, Benzinga Editor. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage …Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Nov 30, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00. Jun 30, 2023 · VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 9,622,300 $ 16,637,600 Prepaid expenses and other current assets 1,889,400 802,700 Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...
Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...
Vistagen common stock will begin trading. SOUTH SAN FRANCISCO, Calif., June 06, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment ...With FDA feedback confirming the acceptable use of the LSAS as a primary efficacy endpoint, Vistagen is positioned to finalize key components of its potential New Drug Application (NDA)-enabling development program for fasedienol for treatment of SAD. Dr. Michael R. Liebowitz, a Columbia University psychiatrist, former director and founder …VistaGen drops 80% as late-stage study for anxiety therapy fails. Clinical-stage biotech VistaGen Therapeutics ( NASDAQ: VTGN) announced on Friday that the company’s PALISADE-1 Phase 3 clinical ...Find the latest Vistagen Therapeutics, Inc. (VTGN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Historical daily share price chart and data for VistaGen Therapeutics since 2016 adjusted for splits and dividends. The latest closing stock price for ...
The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...
2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.
At one point Monday, investors shot up the value of Vistagen's stock (NASDAQ: VTGN) more than 1,300% to $24.71 per share before it settled at $13.05. Vistagen shares had closed Friday at $1.68.Vistagen Therapeutics, Inc. (VTGN) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » VTGN Vistagen Therapeutics, Inc. …Aug 7, 2023 · Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ... Vistagen Therapeutics’ fast-acting nasal spray drug, fasedienol, hit primary and secondary goals of an abbreviated late-stage study in social anxiety disorder. Vistagen’s stock price rocketed ...Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 6, 2023-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call …Next quarter’s earnings estimate for VTGN is -$0.68 with a range of -$0.68 to -$0.68. The previous quarter’s EPS was -$0.94. VTGN beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the …Nov 6, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ... 2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.What is Vistagen Therapeutics, Inc. (VTGN)'s stock price history? Over the last year, Vistagen Therapeutics, Inc.’s stock price has decreased by 7.38%. Vistagen Therapeutics, Inc. is currently ... On Tuesday 10/24/2023 the closing price of the VistaGen Therapeutics Inc Registered Shs share was $3.07 on NAS. Compared to the opening price on Tuesday 10/24/2023 on NAS of $2.99, this is a gain ...The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...
Based on short-term price targets offered by two analysts, the average price target for VistaGen Therapeutics, Inc. comes to $12.00. The forecasts range from a low of $12.00 to a high of $12.00 ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for ...
Apr 20, 2023 · SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ... Every investor in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) should be aware of the most powerful shareholder groups. We can see that retail investors own the …VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss SA News Fri, Aug. 12, 2022 2 Comments VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M ...Aug. 10, 2023 5:22 PM ET Vistagen Therapeutics, Inc. (VTGN) By: Deepa Sarvaiya, SA News Editor 2 Comments VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q1 GAAP EPS of -$0.94 misses by $0.08 .Aug 7, 2023 · Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ... Get a real-time VistaGen Therapeutics, Inc. (VTGN) stock price quote with breaking news, financials, statistics, charts and more.Passion and purpose to transform patient journeys in anxiety and depression. VistaGen Therapeutics' is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders.
Vistagen Therapeutics Inc ( VTGN) is up 6.73% today. VTGN has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.12 and is up $0.21 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between …
Nov 24, 2023 · 33. Shawn Singh. https://www.vistagen.com. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates ...
Nov 30, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00. Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.According to data from Benzinga Pro, VistaGen Therapeutics shares were up 17.6%, trading at $0.16 at the time of publication. The stock has a 52-week high of $1.79 and a 52-week low of $0.08.VistaGen's history tends to make investors cautious with 2012 stock price highs of >$60/share to lows of $0.32/share. This is the complication with biotechnology stocks and failed late-stage ...William Blair initiated coverage on VistaGen Therapeutics Inc VTGN, a clinical-stage biopharmaceutical company focused on developing next-generation …Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ...Nov 30, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00. Find the latest SEC Filings data for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.VistaGen Therapeutics, Inc. Common Stock (VTGN) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.Dec 1, 2023 · Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ... Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Historical daily share price chart and data for VistaGen Therapeutics since 2016 adjusted for splits and dividends. The latest closing stock price for ...Feb 7, 2023 · Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022. VistaGen Therapeutics information: analysis, Share Price, stock price history, price chart, dividends, financials, key metrics, number of shares, ...Instagram:https://instagram. time to buy bondsbnd ex dividend datestart engine investmentwm stock dividend Analyst Recommendations on Vistagen Therapeutics, Inc. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. 2022. MT. William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform. 2022. what is the most expensive houseodfl news Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. We ... celg stock In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in recent years is crafting and building.VTGN Stock Shows Promising Signs for Investors with Potential for Significant Growth. VTGN stock performances on November 7, 2023, showed promising signs for investors. According to data from CNN Money, the 12-month price forecasts for Vistagen Therapeutics Inc had a median target of $12.00, with both the high and low …